Background: Tigecycline, a glycylcycline antibiotic is a promising option for the treatment of single or multidrug resistant pathogens. The aim of the study was to evaluate the in-vitro Tigecycline susceptibility of various pathogens from clinical samples received at the tertiary care hospitals in South India.

Methods: The analysis of specimens from patients admitted were carried out in this prospective cross sectional study. The identification and antimicrobial susceptibility testing was performed by semi-automated Vitek 2 systems and Kirby Bauer method. Pattern of data analysis was done by descriptive statistics.

Results: Among 2574 isolates, 812 isolates were Gram positive pathogens and 1762 isolates were Gram negative pathogens. Resistance to Tigecycline was more common among Gram negative pathogens (18.62%) in comparison to the Gram positive pathogens (0.49%). Among 740 Extended Spectrum Beta Lactamases (ESBL) producers such as species & , 629 isolates were susceptible, and 93 isolates were resistant to the tigecycline. All the methicillin resistant (MRSA) isolates were susceptible to tigecycline.

Conclusion: Multidrug resistant (MDR) pathogens like species, and species were found to be highly effective to tigecycline for elimination of infections caused by both Gram positive and Gram negative pathogens. The use of combination therapy becomes crucial to prevent the development of Pan Drug resistance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11170064PMC
http://dx.doi.org/10.12688/f1000research.141535.2DOI Listing

Publication Analysis

Top Keywords

multidrug resistant
12
gram positive
12
gram negative
12
negative pathogens
12
pathogens
9
resistant pathogens
8
tertiary care
8
isolates gram
8
positive pathogens
8
isolates susceptible
8

Similar Publications

Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains a global health crisis, especially in sub-Saharan Africa, where high human immune virus (HIV) prevalence exacerbates the problem. The co-infection of TB and HIV creates a deadly combination, increasing susceptibility and complicating disease progression and treatment. Ethiopia, classified as a high-burden country, faces significant challenges despite efforts to reduce co-infection rates.

View Article and Find Full Text PDF

Trends in the epidemiology of intravascular device-associated bacteremia among French hematology patients: insights from the SPIADI prospective multicenter study, 2020-2024.

Ann Hematol

January 2025

Mission Nationale Surveillance et Prévention des Infections Associées aux Dispositifs Invasifs (SPIADI), Centre d'Appui pour la Prévention des Infections Associées aux Soins en région Centre val de Loire, Centre Hospitalier Régional Universitaire, Hôpital Bretonneau, Tours, France.

Hematology patients require central venous catheters for cancer treatment and nutrition, which increases their risk of intravascular device-associated bacteremia. In the absence of recent data, we investigated intravascular device-associated bacteremia in this specific context. A three-month surveillance was conducted annually in 27 hematology wards, using a protocol derived from the HAI-Net ICU ECDC protocol (2020-2024).

View Article and Find Full Text PDF

Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii.

Sci Rep

January 2025

Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Acinetobacter baumannii, an opportunistic bacterium prevalent in various environment, is a significant cause of nosocomial infections in ICUs. As the causative agent of pneumonia, septicemia, and meningitis, A. baumannii typically exhibits multidrug resistance and is associated with poor prognosis, thus led to a challenge for researchers in developing new treatment and prevention methods.

View Article and Find Full Text PDF

Dealing With Antibiotic Prophylaxis in Lung Transplantation in the Era of Multidrug Resistance: The Milano Algorithm.

Transplant Proc

January 2025

Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Infectious complications significantly impact morbidity and mortality following lung transplantation (LuTx), with over 25% of post-transplant deaths attributed to infections. Antibiotic prophylaxis during the surgical procedure is crucial for reducing early infections, though the current use of wide-spectrum antibiotics, especially in cases of multidrug-resistant organisms (MDROs), is contentious and varies widely across centre. This practice raises concerns about antimicrobial resistance (AMR), particularly in immunosuppressed patients requiring lifelong healthcare access.

View Article and Find Full Text PDF

Fangchinoline eliminates intracellular Salmonella by enhancing lysosomal function via the AMPK-mTORC1-TFEB axis.

J Adv Res

January 2025

Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, China; Joint International Research Laboratory of Agriculture and Agri-Product Safety, the Ministry of Education of China, Yangzhou University, Yangzhou, China; Institute of Comparative Medicine, Yangzhou University, Yangzhou, China. Electronic address:

Introduction: Salmonella, a foodborne zoonotic pathogen, is a significant cause of morbidity and mortality in animals and humans globally. With the prevalence of multidrug-resistant strains, Salmonellosis has become a formidable challenge. Host-directed therapy (HDT) has recently emerged as a promising anti-infective approach for treating intracellular bacterial infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!